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Cancer of the vulva is a rare female genital neoplasm which repre-
sents 2.5% of cancer cases among women and 5% of all gynecological
malignancies (Hacker, 2000). It occurs most frequently in women be-
tween the ages of 65 and 75 and the most common histological type
is squamous cell carcinoma followed by melanoma, basal cell carcino-
ma and adenocarcinoma (Hacker, 2000). Standard therapy for local
vulvar carcinoma includes radical local excision with or without
inguino-femoral lymphadenectomy, combined with radiotherapy
or chemoradiation for locally advanced or unresectable disease.
The prognosis is generally good when using this multimodality
approach; however, treatments are associated with signiﬁcant mor-
bidity and 40%–50% will eventually develop recurrence (Hacker,
2000; Lupi et al., 1996).
Epidermal growth factor receptor (EGFR) is over-expressed in a
variety of cancers, including both primary vulvar squamous cell carci-
noma and metastatic lesions (Johnson et al., 1997). EGFR is a cellular
transmembrane receptor activated by the binding of EGF or another
growth factor. Activating mutations and ampliﬁcation of the EGFR in-
duce intrinsic tyrosine kinase activity and cellular signaling that re-
sults in cell growth, proliferation, invasion, angiogenesis, metastasis
and inhibition of cell death (Henson and Gibson, 2006).
Erlotinib (Tarceva®) is an oral, reversible EGFR tyrosine-kinase in-
hibitor. The drug received US Food and Drug Administration approval
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Open access under CC BY-NC-ND license.treatment of patients with pancreatic cancer in 2005. The ﬁrst experi-
ence with erlotinib in the treatment of two elderly patients with lo-
cally advanced vulvar cancer was reported in 2007; in both cases,
dramatic responses were observed (Olawaiye et al., 2007).
In this report, we describe the case of a patient with a recurrent
squamous cell vulvar carcinoma after surgery and chemoradiation
who responded to erlotinib during 9 months with excellent
tolerability.
Case presentation
A 76-year old woman presented to the hospital with a six-month
history of a left vulvar lesion. Hypertension well controlled was her
main co-morbidity. Clinical examination showed a 12 cm exophytic
left vulvar mass (Fig. 1). CT-scan and MRI showed a heterogeneous
vulvar mass with left inguinal lymph node involvement. Diagnosis
was established on a biopsy of the mass showing an inﬁltrating well
differentiated squamous cell carcinoma. The tumor was at least
FIGO (International Federation of Gynecology and Obstetrics) stage
IIIA. The patient underwent two cycles of induction chemotherapy
with ﬂuorouracil and cisplatin before chemoradiation; the latter
was combined with a daily fraction of radiotherapy (total dose
46 Gy) and concurrent weekly carboplatin. The tumor and lymph
nodes shrank by 80% and 40% respectively. Six weeks later, a radical
left hemivulvectomy with homolateral lymph node dissection was
performed. Post-operative histology showed important signs of a re-
gression of the primary (>50%) and only one lymph node involved
out of ﬁve. Eleven months after surgery, the patient presented with
a large local recurrence not amenable to surgery. Two cycles of
5-ﬂurouracil and cisplatin were delivered but could not prevent
disease progression. Symptoms included perineal pain, bleeding, in-
ability to sit and loss of weight.
The patient started erlotinib at a dosage of 150 mg daily. The tumor
remained stable for 9 monthswith signiﬁcant improvement of pain and
bleeding and decrease of the uptake of analgesics. The patient could sit
again. Toxicity included grade 2 skin rash. Evaluation after 9 months of
treatment showed eventually a clear disease progression and erlotinib
was stopped. The patient died 1 month later under symptomatic cares.
Discussion
In locally advanced vulvar cancer, recurrence occurs in about half
of the patients after primary treatment including surgery with or
Fig. 1. Exophytic left vulvar mass.
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come depend on the site and extent of recurrence. Local recurrences
without regional node involvement can be managed successfully in
many instances by repeated local excision and/or radiation therapy
providing an approximate 5-year survival rate of 56%. Recurrent le-
sions in the lymph node area not amenable to surgery or radiothera-
py, as well as in distant sites, are more difﬁcult to treat, and the 5-year
survival rate is generally less than 5% (Lupi et al., 1996).
The role of chemotherapy, in this setting, is very limited and the goal
is only palliative. Drugs that have been used include cisplatin, bleomycin,
methotrexate and more recently paclitaxel and vinorelbine with mini-
mal activity in frequently heavily pretreated patients (Deppe et al.,
1979). There is clearly a need for more effective therapeutic approaches.
Using an EGFR inhibitor like erlotinib in vulvar cancer supported by
the known EGFR overexpression which occurs in 60–70% of primary
vulvar squamous cell carcinoma is associated with a poor outcome.
Johnson et al. reported that there is a progressive increase in EGFR
expression in a similar patient, from benign vulvar epithelium
(31%) to primary malignant tissue (65%) and then to metastatic
lesions (88%). The 5-year disease free survival was signiﬁcantly
worse when EGFR levels in the primary tumor was ≥90% vs b90%:
(25% vs 54% respectively—pb0.05) (Oonk et al., 2007). Additionally, inthe study by Oonk et al. EGFR expression was present in 68% of vulvar
tumors and was related to the presence of lymph node metastases
(Oonk et al., 2007). More recently, the ampliﬁcation of the EGFR gene
was reported as conferring a decreased survival, in a cohort of 51 vulvar
cancer patients (Growdon et al., 2008).
In 2007, Olawaiye et al. published the ﬁrst two cases of locally ad-
vanced squamous cell vulvar carcinoma treated with erlotinib at a dos-
age of 150 mg daily. Dramatic responses were observed in both cases
before the third week of treatment but both patients died of several
co-morbidities and the duration of responses was limited (1 and
2 months) (Olawaiye et al., 2007). In our case, the tumor remained sta-
ble for 9 months with signiﬁcant palliation of symptoms. To our best
knowledge, this is the longest response published of a case of vulvar car-
cinoma treated with erlotinib.
Erlotinib is an oral medication that can be taken at home by older
patients with decreased cost and hospital stay and a good tolerability.
In this view, it appears as an attractive alternative treatment for ad-
vanced vulvar carcinoma. Other EGFR inhibitors have been investigat-
ed for treatment of vulvar squamous cell carcinoma. A combination of
cetuximab (anti-EGFR monoclonal antibody) and cisplatin was efﬁ-
cient in one patient with recurrent metastatic vulvar carcinoma
(Richard et al., 2008). Geﬁtinib, another EGFR inhibitor combined
with trastuzumab, an anti-HER2 (human epidermal growth factor
receptor 2) has been investigated in a human vulvar carcinoma cell
line (A431), and seems to increase radiosensitivity (Fukutome et al.,
2006).
Conclusion
As shown in this case report, the potential effect of erlotinib for
vulvar carcinoma, seems to be an important area of research for this
disease and deserves further evaluation in well designed studies.
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